Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.

Abstract

Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.

• Authors: Silke Polsfuss, Sabine Hofmann-Thiel, Matthias Merker, David Krieger, Stefan Niemann, Holger Rüssmann, Nicolas Schönfeld, Harald Hoffmann, Katharina Kranzer
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 69 Issue 7 Pg. 1229-1231 (09 13 2019) ISSN: 1537-6591 [Electronic] United States
• PMID: 30933266 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

Chemical References

• Antitubercular Agents
• Diarylquinolines
• Nitroimidazoles
• OPC-67683
• Oxazoles
• bedaquiline

Topics

• Antitubercular Agents (pharmacology, therapeutic use)
• Diarylquinolines (pharmacokinetics, therapeutic use)
• Drug Resistance, Bacterial
• Drug Therapy, Combination
• Extensively Drug-Resistant Tuberculosis (diagnosis, drug therapy, microbiology)
• Humans
• Male
• Microbial Sensitivity Tests
• Middle Aged
• Mycobacterium tuberculosis (drug effects)
• Nitroimidazoles (pharmacology, therapeutic use)
• Oxazoles (pharmacology, therapeutic use)
• Treatment Outcome